Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Sanwire agrees to acquire Australia's Bateau Asset Management

Sanwire agrees to acquire Australia's Bateau Asset Management

BitgetBitget2026/10/21 12:45
  • Sanwire agreed to acquire 100% of Australia-based Bateau Asset Management, with closing expected in the fourth quarter of 2026.
  • Consideration includes 1,424,115 shares of Series G Preferred Stock convertible into common stock.
  • A USD 250,000 convertible promissory note matures October 1, 2028, with no interest for the first 12 months.
  • The deal also includes a USD 100,000 cash payment payable in interest-free installments over three years.
  • Bateau's Global Opportunities Fund had net assets exceeding USD 7.5 million as of July 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanwire Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610210845PRIMZONEFULLFEED9849680) on October 21, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss